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A B S T R A C T
Purpose: The prevalence of epilepsy in Cameroon is higher than that of the industrialized world and other
developing countries. Neurocysticercosis due to Taenia solium infestation has been reported as a major
cause of epilepsy in some parts of Cameroon although there are some conﬂicting data. The prevalence of
epilepsy is especially high in the Momo division of the North-West Province of Cameroon. We
hypothesized that individuals with epilepsy in this region have a higher percentage of seropositivity to T.
solium than matched controls.
Methods: We conducted a case–control study in the Momo subdivision of Ngie. Individuals with epilepsy
were recruited from the health centers in Ngie. Control subjects were selected from 19 Ngie villages.
Potential cases of people with epilepsy (PWE) were identiﬁed through a questionnaire applied by trained
ﬁeld workers, using history of epileptic seizures as a key indicator. Blood samples were taken from all
consenting individuals by ﬁnger prick, stored in StabilZyme Select, and assayed for antibodies to T. solium
in an Atlanta based reference laboratory.
Results: We accrued 249 patients with epilepsy, of whom 237 met the inclusion criteria, and 245 age-
matched controls. There was no signiﬁcant difference in seropositivity to T. solium between those
individuals with epilepsy (5%) and controls (4.9%).
Conclusions: Our data do not support the hypothesis that epilepsy is associated with seropositivity to T.
solium. It is highly unlikely that cysticercosis plays a causative role in the high prevalence of epilepsy in
this region of Cameroon.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Similar to many countries in Africa, the prevalence of epilepsy
in Cameroon is higher than that in industrialized countries and has
been reported to vary from 5.5 to 136 per thousand population.1–5
The variability in reports may be due to methodological
differences. It is also possible that variability could be due to
differences in etiology between regions in Cameroon. Ngie is one of
the four administrative subdivisions of the Momo Division in
North-West Cameroon and comprises 19 villages, all found within* Corresponding author at: Division of Neurology, Hospital for Sick Children, 555
University Avenue, Toronto, Ontario M5G 1X8, Canada. Tel.: +1 416 813 7851;
fax: +1 416 813 6334.
E-mail address: carter.snead@sickkids.ca (O.C. Snead III).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.01.012the Mbengwi Health District. Local health care providers have
reported a high prevalence of epilepsy in the adult population [J.
Ambanibe & A. Kourosh, personal communication]. The population
of Ngie is approximately ﬁfty thousand people. A 2003 survey of all
households in the 19 villages of Ngie identiﬁed approximately 500
persons (10/1000) with epilepsy [J. Ambanibe, personal commu-
nication]. Epilepsy in Ngie appears to be an early childhood onset
disorder that lasts well into adulthood, being life-long in most
cases. Unconﬁrmed reports indicate that in most individuals the
seizures appear to be primary generalized, but in some cases
appear to be focal in onset (e.g. blinking, staring, visual
phenomena, etc.), with evolution to generalized convulsions.
There are many anecdotal accounts of severe seizure-related
injuries in Ngie including burns and falls, as well as deaths from
uncontrolled status epilepticus and drowning.vier Ltd. All rights reserved.
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not been determined. Neurocysticercosis arising from Taenia
solium infection has been postulated to be the major cause of
epilepsy in some parts of Cameroon, as it is in other developing
countries.6–8 Zoli et al.9 in an uncontrolled study in three rural
localities in the West and North-West regions of Cameroon, used
an enzyme-linked immunosorbent assay for both circulating
antigen (Ag-ELISA) and antibody (Ab-ELISA) detection in individu-
als who had epilepsy. These authors concluded that T. solium
cysticercosis appeared to be an important cause of epilepsy in
Cameroon; however, this ﬁnding has not been conﬁrmed in all
studies,1 suggesting that the etiology of epilepsy may vary by
region.2,10
Throughout the North-West region of Cameroon, including the
Momo division, pig rearing is very common and pigs are often kept
in close proximity to houses. Since neurocysticercosis is endemic
in less developed countries where pigs are raised as a food
source,11,12 this factor raises the question of whether neurocys-
ticercosis has a causative role in the incidence of epilepsy in this
region. The purpose of this study was to test the hypothesis that
neurocysticercosis is responsible for the high prevalence of
epilepsy in the Ngie sub-division of Momo. More speciﬁcally,
the primary objective was to compare the serological status of T.
solium in individuals with epilepsy with matched, unrelated, case
controls in the sub-division of Ngie. A secondary objective was to
obtain a demographic proﬁle of those individuals identiﬁed with
epilepsy in this region, including other potential risk factors for
epilepsy.
2. Methods
2.1. Ethics approvals and consent
This study was carried out under the ethical precepts found in
the World Medical Association Declaration of Helsinki (http://
www.wma.net/e/policy/b3.htm). Ethics approval was obtained
from the Research Ethics Board of the Hospital for Sick Children,
Toronto, Canada, the Cameroon National Ethics Committee, and
the local district ethics committee (Alpha Royal Clinic). Commu-
nity consent was ﬁrst obtained by having medical health
volunteers explain the goal of the study to village traditional
and administrative and health authorities. Community informa-
tion sessions were then conducted, the purpose of which was to
allow individuals to discuss their questions and concerns. Village
coordinators, who helped study participants to complete the
questionnaires, were trained on how to obtain informed consent.
In addition, the coordinators determined who could read. Ngie
language is not written. Therefore, to make things clear, a
translated version of the informed consent was made on an
audiotape and played where necessary. Following these commu-
nity meetings, potential subjects and controls were provided
further information and if they agreed to participate, consent for
the administration of the questionnaire and blood sampling was
obtained.
2.2. Participants
Individuals with epilepsy were recruited from local households
in the 19 villages and from the two health centers (clinics) in the
sub-division of Ngie, Momo Division, North-West Cameroon.
Persons with epilepsy had been attending these health centers for
distribution of antiepileptic medication (phenobarbital). Those
with epilepsy were deﬁned as having had at least two unexplained
and unprovoked seizures occurring within a time range of >24 h.
This was to include all types of partial and/or generalized
seizures.13 A total of 57 persons with epilepsy were excludedfor the following reasons. In order to eliminate neonatal seizures
and febrile seizures, individuals with seizure onset under four
years of age were excluded. Similarly, in order to eliminate seizures
associated with cerebrovascular disease and dementing illnesses,
individuals in whom seizure onset occurred over 60 years of age
were also excluded. Between the 2003 survey and 2008 (time of
the study), approximately 45 individuals had died from epilepsy
related events, including drowning, burns, and suffocation [J.
Ambanibe, personal communication]. Of the estimated 398
remaining individuals with epilepsy, approximately 100 individu-
als were unable to travel to a health center for the study because of
a serious illness (e.g. malaria) or because of the distance [J.
Ambanibe, personal communication]. We were unable to account
for a further 45 persons identiﬁed with epilepsy in the 2003 survey.
It has been proposed that at least some of these individuals may
have died from non-epilepsy related causes [J. Ambanibe, personal
communication]. All other individuals (n = 249) approached
agreed to participate. It is possible that some of the 45 individuals
with epilepsy unaccounted for may be due to the stigma attached
to epilepsy. However, our communication with health team
members suggest that most individuals with epilepsy, and their
families, participated with a hope that this study might provide
information about the cause of their epilepsy.
Controls with no history of epilepsy from the 19 villages in Ngie
sub-division volunteered to participate after hearing about the
study at community meetings and from village coordinators. They
were then matched for age and sex by group with subjects in the
epilepsy group. Exclusion criteria for controls were a history of
epilepsy in the subject or in the family. It should be noted however,
that it was difﬁcult to be completely sure whether controls were
distantly related to subjects with epilepsy.
2.3. Questionnaires
An adapted form of a previously validated epilepsy screening
questionnaire14 was applied by trained ﬁeld workers to identify
potential people with epilepsy. This questionnaire was developed
for the detection of epileptic seizures in epidemiological studies in
developing countries. This questionnaire has been validated on a
population of 72,121 people, and has been shown to have a
sensitivity of 79.3%, a speciﬁcity of 92.9%, a positive predictive
value of 18.3% and a negative predictive value of 99.6%.14,15
Following completion of this validated epilepsy questionnaire,
participants completed a second, more comprehensive, demo-
graphic/medical questionnaire developed in Limoges France, and
was previously and has been validated and used by the Pan African
Association of Neurological Sciences in many African countries,
including Cameroon.4,5,16 Except for the demographic and epilep-
sy-related data, the results from this questionnaire are beyond the
scope of the current paper.
2.4. Procedure
Individuals in 19 villages were designated as coordinators and
trained to administer the screening questionnaire. Training was
completed by a local investigator (JA) and a member of the
research team from Canada (IE).
Potential participants from each village in Ngie were screened
door to door by the village coordinators to identify all individuals
who had epilepsy and to obtain volunteers for the control group.
Those consenting to participate were convened to the nearest local
health center, where a local physician with special training in
neurology/epileptology (SAA) reviewed each individual’s medical
history, and further conﬁrmed those with a history of epilepsy and
the respective controls. Some individuals who initially presented
themselves as controls were examined and discovered to be
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subjects. Others presented themselves as having epilepsy, but
had only experienced either one epileptic seizure or were deemed
not to have had epileptic seizures, and were thus excluded from the
study. In either case they were referred to the nearest health
facility for assessment. Medication (phenobarbital) was prescribed
to newly diagnosed patients and minor dose adjustments were
made for people with uncontrolled seizures. All patients were
referred to the health centers for follow-up.
2.5. Blood sampling/serology
Supplies for blood samples were brought to Cameroon by a
research team member (IE) from Canada. The drawing of blood for
serologies, storage of serology samples, and transfer of all serology
samples for analysis to the Centers for Disease Control in Atlanta
(CDC) was coordinated by the local team of investigators (IT, JA,
AKN). The method used for collecting measured whole blood with
quantitative recovery of antibodies to T. solium was described by
Handali et al.17 Brieﬂy, blood samples were obtained by a qualiﬁed
medical technician under sterile conditions by ﬁnger stick, and
were collected on ﬁlter paper, which was immediately immersed
in extraction/preservative (StabilZyme TM) and frozen. Blood
samples from both the epilepsy and control groups were obtained
at one of two health centers. The samples were stored at the
Catholic Medical Health Centre, Mambu Bafut until shipped in cold
packs to the CDC for detection of T. solium speciﬁc antibodies using
the lentil lectin afﬁnity-puriﬁed glycoprotein antigen enzyme-
linked immunotransfer blot (LLGP-EITB). Reactivity with any one
of seven glycoprotein antigens (gp50, 42, 24, 18, 14, and 13) was
considered a positive result.18–20 The sensitivity of the LLGP-EITB is
reported to be 98% and its speciﬁcity reaches 100% in patients with
two or more viable brain lesions as demonstrated by neuroimag-
ing.19,20
2.6. Data analysis
Differences between the individuals with epilepsy and controls
were examined using t-tests for continuous variables and chi
square tests for categorical variables.
3. Results
3.1. Demographics
We accrued 249 individuals with epilepsy and 245 age-
matched controls (Table 1). Of those with epilepsy who
participated in this study, 12 reported an age of seizure onset
less than 5 years of age and thus are excluded from this report.
Another 15 individuals did not report age of seizure onset, but were
included in the sample. The mean age of control subjects was 17.5
years and that of the epilepsy group was 18.3 years (t = 1.56,Table 1
Epilepsy and control groups.
Epilepsy Controls
Sex (M/F) % 53/47 57/43
Mean age (SD) 18.3 (7.2) 17.5 (9.8)
Range 8–60 6–76
Mean age at seizure onset (SD) 12.2 (5.6) n/a
Range 5–53
Type of seizure (%)
Generalized tonic clonic 68.0
Partial  28 generalized 23.9 n/a
Other 8.1
Relatives with epilepsy (%) 59.9 0
Seropositivity to Taenia solium (number (%)) 11 (4.4) 13 (5.5)p > 0.1). There were 53% male and 47% female in the epilepsy
group and 57% male and 43% female in the control group (x2 = 1.25,
p > .0.1). Mean age of seizure onset was at 12.2 years. Sixty-eight
percent (68%) of the epilepsy group had generalized convulsive
seizures with 24% having localization-related epilepsy with
secondary generalized seizures. Sixty percent (60%) of the
individuals with epilepsy reported having relatives with epilepsy.
The majority (67.7%) of the individuals with epilepsy began to have
seizures at age 12 years or younger; 26.8% had onset in the teen
years, 4.1% between the ages of 20 and 29, and 1.4% over the age of
40. Table 1 provides further details of the demographic and
seizure-related variables.
Analysis of data on potential risk factors for epilepsy revealed
that prematurity, excessive alcohol consumption in the past,
excessive drug use, as well as encephalitis, encephalopathy, and
meningitis in childhood were not signiﬁcant. Head injury with loss
of consciousness was signiﬁcant (p < .01) with a higher number of
epilepsy cases (n = 18) than controls (n = 7). Measles in childhood
approach signiﬁcance (p < .057) with a somewhat higher rate
amongst the epilepsy cases (n = 65) than those in the control group
(n = 46).
3.2. Serology
Of the 494 samples tested, only 24 samples were positive on
LLGP-EITB for cysticercosis. It should be noted that although they
were not included in the analysis, none of the twelve individuals
with seizure onset under 5 years of age were seropositive. Further,
there was no signiﬁcant difference in sero-positivity to T. solium
between those with epilepsy (n = 11; 4.4%) and the controls
(n = 13; 5.3%) (Table 1).
4. Discussion
Our data do not appear to support the hypothesis that
individuals with epilepsy from Ngie have a higher percentage of
seropositivity to T. solium than a matched control population.
However this conclusion is limited somewhat by the fact that
neurocysticercosis is a major cause of focal epilepsy and we
included patients with both generalized and focal epilepsy in our
study. This strategy was dictated by our inability to deﬁne focal
epilepsy precisely using electroencephalography (EEG) given the
absence of this resource in rural Cameroon. It is notoriously
difﬁcult to select out focal epilepsy based upon seizure semiology
alone in patients who present with a history of generalized
epilepsy because of the subtleties of secondarily generalized
epilepsy. An example of the value of EEG in resolving this
conundrum, as well as the over representation of focal epilepsy in
patients in Cameroon with epilepsy may be found in the study by
Prischich5 where partial seizures deﬁned by EEG were determined
to represent 47% of patients based on seizure semiology before EEG
and 64.7% following EEG.
With that caveat, these data appear to make it unlikely that
neurocysticercosis plays a causative role in the high prevalence of
epilepsy in this speciﬁc area of Cameroon and is in agreement with
the report of Dongmo and collaborators.1 As well, we examined a
number of other potential risk factors, including prematurity,
alcohol and drug abuse, encephalitis, encephalopathy, meningitis,
head injury and measles. Only head injury reached signiﬁcance,
with a greater number of epilepsy cases reporting a history of head
injury with loss of consciousness. However, these numbers are too
small to account for the high rate of epilepsy. Further, our study
design does not allow us to conclude what the causes of epilepsy in
this area might be.
Given our negative ﬁndings, the cause of the high rate of
epilepsy in Ngie remains unknown. In the sample with epilepsy it
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majority (almost 70%) had their ﬁrst seizure before the age of 12
years. Although most PWE we surveyed (68%) had generalized
seizures, it is possible that some individuals had partial seizures
that secondarily generalized but could not be identiﬁed as such
because of recall bias or an inaccurate description of seizures. Fifty-
nine percent (59%) of PWE had at least one family memory with
epilepsy. These ﬁgures raised the possibility of a genetic etiology.5
A second candidate for causation would be other parasitic
diseases, such as Onchocerca volvulus, the causative agent in
onchocerciasis (river blindness). A number of studies have
suggested an association between onchocerciasis and epilepsy
in other regions of Cameroon as well as in other countries in west,
central and east Africa.2,21,22 Local health workers recently
conﬁrmed that onchocerciasis is common in Ngie [J. Ambanibe,
personal communication], and it remains to be determined
whether this parasite could account for the high rate of epilepsy.
In addition to the concern expressed above re focal epilepsy,
there are additional limitations to this study. First, we did not do CT
scans on the epilepsy and control cohorts, Since CT is the gold
standard for making the diagnosis of neurocysticercosis, we cannot
conﬁrm whether any of the participants had this disorder. It simply
was not possible to perform a CT scan on our subjects given the
severe limitations of resources in the rural part of Cameroon in
which this study was carried out. For the same reasons, even a
simple skull ﬁlm to look for intracranial calciﬁcations was not
feasible. Second, the detection of antibodies against T. solium by
EITB in blood samples reﬂects a history of contact with the parasite
rather than a real infestation by the metacestodes of T. solium.
However, in some populations associations between seropositivi-
ty, neurocysticercosis and epilepsy have been demonstrated.18
Finally, a major consideration for working in the ﬁeld in rural
Cameroon is that the Agn ELISA cannot be performed on ﬁngerstick
blood. It was never practical or feasible to do venipunctures on our
cohorts.
5. Conclusion
These data do not support the hypothesis that those individuals
in the Ngie sub-division of Momo who have epilepsy have a higher
percentage of seropositivity to T. solium than a matched control
population. The data make it highly unlikely that cysticercosis
plays a causative role in the increased prevalence of epilepsy in this
region of Cameroon. These results and previously published data
suggest that the high prevalence of epilepsy reported in some areas
in Cameroon could be attributed to a combination of many factors
and not just one risk factor.
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